Clinical Trials Logo

Clinical Trial Summary

To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent OCSCC.


Clinical Trial Description

Primary Objective: - To assess the efficacy of cemiplimab and cetuximab in patients with recurrent OCSCC Secondary Objective: - To assess safety of cemiplimab and cetuximab prior salvage surgery - To evaluate the efficacy of cemiplimab and cetuximab prior salvage surgery on measures - To estimate the one-year disease free survival (DFS) - To estimate the median overall survival (OS) Tertiary/Exploratory Objective: - To explore patient-reported outcomes (PRO) during CC and following salvage surgical resection - Assess impact of cemiplimab and cetuximab on surgery and adjuvant therapy - To explore biomarkers that may predict response to therapy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06448026
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Luana Guimaraes De Sousa, MD
Phone (832) 728-7849
Email lgsousa@mdanderson.org
Status Not yet recruiting
Phase Phase 2
Start date November 29, 2024
Completion date May 15, 2027